Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

Letter to the Editor


Aflibercept Treat-and-extend regimen Polypoidal choroidal vasculopathy Central macular thickness Central choroidal thickness 


Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol, Published online: July 01, 2017
  2. 2.
    Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K (2013) Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol 91(6):e474–e481CrossRefPubMedGoogle Scholar
  3. 3.
    Jeong S, Sagong M (2017) Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 101(6):758–763CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Comparison of time to retreatment and visual function between ranibizumab and aflibercept in age-related macular degeneration. Am J Ophthalmol 174(2):181–182PubMedGoogle Scholar
  5. 5.
    Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar
  6. 6.
    Julien S, Biesemeier A, Taubitz T, Schraemeyer U (2014) Different effects on intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues on monkey eyes. Br J Ophthalmol 98(6):813–825CrossRefPubMedGoogle Scholar
  7. 7.
    Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Heier JS (2016) Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology 123(9):1856–1864CrossRefPubMedGoogle Scholar
  8. 8.
    Hikichi T (2017) Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. Published on May 25, 2017
  9. 9.
    Călugăru D, Călugăru M (2017) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovacular age-related macular degeneration. Am J Ophthalmol 173(1):145–146PubMedGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2017) Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol 174(2):185–186PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-NapocaCluj-NapocaRomania

Personalised recommendations